Literature DB >> 36057735

Taurine, an essential β-amino acid insulates against ketamine-induced experimental psychosis by enhancement of cholinergic neurotransmission, inhibition of oxidative/nitrergic imbalances, and suppression of COX-2/iNOS immunoreactions in mice.

Benneth Ben-Azu1, Olusegun G Adebayo2, Thiophilus Aghogho Jarikre3, Mega O Oyovwi4, Kesiena Emmanuel Edje5, Itivere Adrian Omogbiya5, Anthony T Eduviere5, Emuesiri Goodies Moke5, Bienose S Chijioke5, Onyebuchi S Odili5, Osemudiame P Omondiabge5, Aghogho Oyovbaire5, Daniel T Esuku5, Esther O Ozah5, Kelvin Japhet5.   

Abstract

Cholinergic, oxidative, nitrergic alterations, and neuroinflammation are some key neuropathological features common in schizophrenia disease. They involve complex biological processes that alter normal behavior. The present treatments used in the management of the disorder remain ineffective together with some serious side effects as one of their setbacks. Taurine is a naturally occurring essential β-amino acid reported to elicit antipsychotic property in first episode psychosis in clinical setting, thus require preclinical investigation. Hence, we set out to investigate the effects of taurine in the prevention and reversal of ketamine-induced psychotic-like behaviors and the associated putative neurobiological mechanisms underlying its effects. Adult male Swiss mice were sheared into three separate cohorts of experiments (n = 7): drug alone, preventive and reversal studies. Treatments consisted of saline (10 mL/kg/p.o./day), taurine (50 and 100 mg/kg/p.o./day) and risperidone (0.5 mg/kg/p.o./day) with concomitant ketamine (20 mg/kg/i.p./day) injections between days 8-14, or 14 days entirely. Behavioral hyperactivity, despair, cognitive impairment, and catalepsy were measured. Brain oxidative/nitrergic imbalance, immunoreactivity (COX-2 and iNOS), and cholinergic markers were determined in the striatum, prefrontal-cortex, and hippocampus. Taurine abates ketamine-mediated psychotic-like episodes without cataleptogenic potential. Taurine attenuated ketamine-induced decrease in glutathione, superoxide-dismutase and catalase levels in the striatum, prefrontal-cortex and hippocampus. Also, taurine prevented and reversed ketamine-mediated elevation of malondialdehyde, nitrite contents, acetylcholinesterase activity, and suppressed COX-2 and iNOS expressions in a brain-region dependent manner. Conclusively, taurine insulates against ketamine-mediated psychotic phenotype by normalizing brain central cholinergic neurotransmissions, oxidative, nitrergic and suppression of immunoreactive proteins in mice brains.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Amino acids; Cholinergic deficit; Cognitive deficits; Neuroinflammation; Schizophrenia

Year:  2022        PMID: 36057735     DOI: 10.1007/s11011-022-01075-5

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.655


  85 in total

1.  Morin Attenuates Neurochemical Changes and Increased Oxidative/Nitrergic Stress in Brains of Mice Exposed to Ketamine: Prevention and Reversal of Schizophrenia-Like Symptoms.

Authors:  Benneth Ben-Azu; Adegbuyi Oladele Aderibigbe; Aya-Ebi Okubo Eneni; Abayomi Mayowa Ajayi; Solomon Umukoro; Ezekiel O Iwalewa
Journal:  Neurochem Res       Date:  2018-06-28       Impact factor: 3.996

2.  Probable mechanisms involved in the antipsychotic-like activity of morin in mice.

Authors:  Benneth Ben-Azu; Adegbuyi Oladele Aderibigbe; Itivere Adrian Omogbiya; Abayomi Mayowa Ajayi; Olatunde Owoeye; Elizabeth Toyin Olonode; Ezekiel O Iwalewa
Journal:  Biomed Pharmacother       Date:  2018-06-20       Impact factor: 6.529

3.  Morin decreases cortical pyramidal neuron degeneration via inhibition of neuroinflammation in mouse model of schizophrenia.

Authors:  Benneth Ben-Azu; Adegbuyi Oladele Aderibigbe; Abayomi Mayowa Ajayi; Aya-Ebi Okubo Eneni; Itivere Adrian Omogbiya; Olatunde Owoeye; Solomon Umukoro; Ezekiel O Iwalewa
Journal:  Int Immunopharmacol       Date:  2019-03-07       Impact factor: 4.932

4.  Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation.

Authors:  L V Borovikova; S Ivanova; D Nardi; M Zhang; H Yang; M Ombrellino; K J Tracey
Journal:  Auton Neurosci       Date:  2000-12-20       Impact factor: 3.145

5.  Involvement of GABAergic, BDNF and Nox-2 mechanisms in the prevention and reversal of ketamine-induced schizophrenia-like behavior by morin in mice.

Authors:  Benneth Ben-Azu; Adegbuyi Oladele Aderibigbe; Abayomi Mayowa Ajayi; Aya-Ebi Okubo Eneni; Solomon Umukoro; Ezekiel O Iwalewa
Journal:  Brain Res Bull       Date:  2018-03-13       Impact factor: 4.077

Review 6.  Mitochondria, synaptic plasticity, and schizophrenia.

Authors:  Dorit Ben-Shachar; Daphna Laifenfeld
Journal:  Int Rev Neurobiol       Date:  2004       Impact factor: 3.230

7.  Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase.

Authors:  M Margarita Behrens; Sameh S Ali; Diep N Dao; Jacinta Lucero; Grigoriy Shekhtman; Kevin L Quick; Laura L Dugan
Journal:  Science       Date:  2007-12-07       Impact factor: 47.728

8.  N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial.

Authors:  Michael Berk; David Copolov; Olivia Dean; Kristy Lu; Sue Jeavons; Ian Schapkaitz; Murray Anderson-Hunt; Fiona Judd; Fiona Katz; Paul Katz; Sean Ording-Jespersen; John Little; Philippe Conus; Michel Cuenod; Kim Q Do; Ashley I Bush
Journal:  Biol Psychiatry       Date:  2008-04-23       Impact factor: 13.382

9.  Increased number of nitric oxide synthase immunoreactive Purkinje cells and dentate nucleus neurons in schizophrenia.

Authors:  H G Bernstein; D Krell; K H Braunewell; B Baumann; E D Gundelfinger; S Diekmann; P Danos; B Bogerts
Journal:  J Neurocytol       Date:  2001-08

10.  Neuroprotective effects of the ethanol stem bark extracts of Terminalia ivorensis in ketamine-induced schizophrenia-like behaviors and oxidative damage in mice.

Authors:  Benneth Ben-Azu; Adegbuyi Oladele Aderibigbe; Abayomi Mayowa Ajayi; Ezekiel Oluwagbenga Iwalewa
Journal:  Pharm Biol       Date:  2016-06-02       Impact factor: 3.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.